Marketresearchnews

Tuesday, 24 August 2021

Healthcare Contract Manufacturing Market Insights Analysis 2020-2027

Market Scenario

The Global Healthcare Contract Manufacturing Market 2020, according to the MRFR analysis, is poised to mature at a 9.86% CAGR and is projected to reach USD 250.9 Billion by 2023.

Market Dynamics

The expiration of patents for major drugs and medical devices, competition and production and trade economics to favor contract manufacturing organization (CMO), mutual benefit to contract manufacturer and customer, and lean manufacturing and agility are some of the major drivers for the growth of contract manufacturing market for healthcare across the globe. A big patent cliff is occurring worldwide, especially in the pharmaceutical industry, in the healthcare sector. The patent cliff will lead to cheaper generic versions on the market , increasing demand for CMOs. Thus, the expiration of patent protection for major prescription drugs and the increasing demand for generic drugs are likely to enhance the growth of CMOs globally. In the other hand, the uncertainty of the supply chain and third party management problems and standardization and interoperability concerns are anticipated to impede business growth over the projected period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5637

Segmentation

The global market for healthcare contract manufacturing has been analyzed on the basis of service type, type, and lastly, industry.

The type-based segmentation of the global CMO market comprises of sterile and non-sterile.

The service-based segmentation of the global CMO market comprises pharmaceutical industry, medical device industry, and biopharmaceutical industry.

The industry-based segmentation of the global CMO market comprises medical device industry, pharmaceutical industry, and biopharmaceutical industry. Due to the rampant growth of the global medical device industry, the segment of medical devices led the market in 2016 by holding 43.7 per cent market revenue share.

Regional Summary

The global healthcare contract manufacturing market, based on region, is segmented into the Americas, Europe , Asia-Pacific, and Middle East & Africa.

Driven by the presence of major pharmaceutical drug manufacturers, thriving pharmaceutical industry and leading medical device companies in the US and Canada, the Americas currently dominates the global healthcare contract manufacturing market.

Generic drug companies are the main customer base of contract manufacturers in Europe, contributing to the growth of the European CMO market. Important factors influencing European market growth include the presence of major manufacturers, Increase in the biopharmaceutical sector , government support for R&D, increased disposable income and the availability of technologically advanced products.

Asia-Pacific should record a comparatively higher CAGR over the forecast period. Countries like China and India continue to draw significant amounts of outsourcing work from developed countries due to factors such as large-scale production capacity , low labor costs , low cost of raw materials and low cost of manufacturing. Besides that, some of the key factors driving demand growth include rising healthcare spending, increasing manufacturers' R&D funding, and moreover multinational medical device manufacturers seeking opportunities in the region and expanding their presence in the region. The changing regulatory landscape of medical devices has been a concern for the region's contract-manufacturing healthcare market.

The Middle East & Africa contributes least to the global contract manufacturing market in the healthcare sector. The growing development of the medical sector in the Middle Eastern countries, increased R&D spending and the expansion of multinational companies in the region also influence market growth.

Competitive Dynamics

The eminent players in the global healthcare contract manufacturing market are Lonza AG, Boehringer Ingelheim, Grifols International, S.A, Catalant, Aesica Pharmaceuticals, AbbVie, Benchmark Electronics, Evonik Industries, Flex Ltd, Teva Pharmaceutical Industries, Forefront Medical Technologies, Hamilton Company, Sanmina Corporation, Mylan, Patheon, and Vetter Pharma International.

Industry Update

August 2020 - BioStem Technologies, Inc., a leading life sciences company specializing in the development and sale of perinatal tissue-based allografts for use in regenerative therapies, announced that its subsidiary, Blue Tech Industries, Inc. signed a Master Service Agreement with a new customer to manufacture the customer’s amniotic membrane platform for the next two years, in a deal estimated to be worth up to USD 2.4 million to BioStem.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/healthcare-contract-manufacturing-market-5637

About Market Research Future:

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.j

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

Structural Heart Devices Market Growth, Trends and Value Chain 2020-2027

Structural heart disease known as a non-coronary anomaly of the heart, therefore not disturbing the blood vessels in the heart. The structural heart diseases refer to cardiac defects which are inherited by birth and can be developed later in life. Common structural heart condition includes atrial septal defect, ventricular septal defect, paravalvular leak, arterial or venous fistula, patent foramen oval and congenital heart disease. The rise in the frequency of structural heart diseases and a rise in demand for minimally invasive techniques are factors that drive the growth of the market. Advanced products such as sutureless heart valve cost pointedly higher than earlier available products. This double prices of the sutureless device will limit the adoption of the equipment’s, which in turn will restrain the growth of the market.The global structural heart devices market is expected to grow at CAGR of 10.4% during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6385

Segmentation

The global structural heart devices market has been segmented on the basis of type, indication, procedure, and end-user. On the basis of type, the market has been classified as heart valve devices, occluders and delivery systems, annuloplasty rings, accessories, and other devices. The heart valve devices are segmented into transcatheter heart valves and surgical heart valves. The surgical heart valves are further sub-segmented into tissue heart valves and mechanical heart valves. On the basis of indication, the market has been classified as valvular heart disease, cardiomyopathy, congenital heart defects, and others. The valvular heart disease is segmented into regurgitation and stenosis. On the basis of procedure, the market has been classified as Replacement Procedures and repair procedures. The Replacement Procedures is segmented into TAVR procedures and SAVR procedures. The repair procedures are segmented into closure procedures, annuloplasty, valvuloplasty, and TMVR procedures. On the basis of end-users, the market has been classified as hospitals, ambulatory surgery centers, and others.

Regional Analysis

The Americas is projected to lead the structural heart devices market in the forecast period. Rising rate in a number of surgeries due to factors such as diabetes, high blood pressure, and others contribute majorly to the growth of the market. Increasing healthcare awareness, advancement in technology, medical tourism, and an increase in disposable income are some other factors that boost the growth of the market.

The European market is expected to hold the second largest market share as structural heart devices market is most common in Germany. The European market is projected to grow because of the increase in elderly population, growing prevalence of diabetes, and obesity in the region.

Asia-Pacific was projected to be the fastest growing region for the global structural heart devices market in 2018. The market is expected to witness growth owing to the rising patient population, changing lifestyle, and growing elderly population. This is expected to provide favorable backgrounds for the market to grow.

The Middle East and Africa accounts for the least share due to stringent government policies and low per capita income.

Key Players

Some of the key players in the global structural heart devices market are Edwards Lifesciences Corporation (US), Medtronic plc (Ireland), Abbott (US), Boston Scientific Corporation (US), and LivaNova plc (UK), ST. Jude Medical, Biomerics, Comed BV, JenaValve Technology, Inc., CardioKinetix, Cook Group Incorporated (US), Endologix Inc. (US)., and W. L. Gore & Associates, Inc. (US).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/structural-heart-devices-market-6385

About Market Research Future:

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

Healthcare Claims Management Market Growth, Trends and Value Chain 2020-2027

Global healthcare claims management market is expected to grow significantly over the forecast period. It is estimated that the global healthcare claims management market is expected to register a CAGR ~ 5.37% during the forecast period of 2018–2023. Healthcare claims management process comprises of various tasks such as organization, billing, filling, updating, and processing of medical claims related to the diagnosis, treatment, and medication of patients.

The global market is driven by factors such as increase in ageing population, rise in incidence of chronic diseases, improved focus on healthcare quality services and advent of innovative treatments & technologies.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6376

Factors such as increasing concerns regarding the patient data safety and security limit and data breaches and loss of confidentiality, lack of skilled IT professionals in healthcare are restraining the growth of medical claims management solutions market. According to the National Health Insurer Report Card published in 2011 by American Medical Association (AMA), around $17 billion a year (on an average) could be saved by eliminating errors in claims.

Segmentation

The global healthcare claims management solutions market has been segmented into component, delivery mode type and end-user. The market, based on component, has been segmented into software and services. The market, by delivery mode, has been segmented into on-premise and cloud based. The market, by type, has been segmented into integrated and standalone. The market, by end-user has been segmented into healthcare payers and providers.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The healthcare claims management market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European healthcare claims management market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The healthcare claims management market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The healthcare claims management market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

Cerner Corporation (US), McKesson Corporation (US), Athenahealth (US), eClinicalWorks (US), Optum, Inc. (US), Conifer Health Solutions (US), nThrive (US), Avaya Inc. (USA), Oracle Corporation (US), Infor Inc. (US), Allscripts Healthcare Solutions, Inc. (US), Accenture plc. (Ireland), IBM Corporation (US), Cognizant Technology Solutions Corporation (US) and Genpact Limited (US) are some of the key players in the global healthcare claims management market.

Regional Market Summary

Geographically, the Americas is expected to dominate the global healthcare claims management market due to the growing HCIT investments in the region and the presence of regulatory mandates favouring the implementation of healthcare claims management solutions.

Europe is expected to hold the second largest position in the global healthcare claims management market. The market growth in this region is because of the rise in prevalence of chronic diseases, presence of well-established healthcare system and increase in insurance coverage.

Asia-Pacific is estimated to be the fastest growing region in the market due to the improved healthcare infrastructure and increasing geriatric population.

On the other hand, the Middle East & Africa has the least share of the market. This is due to low technological advancements in the field of healthcare IT.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/healthcare-claims-management-market-6376

About Market Research Future:

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

Arrhythmia Monitoring Devices Market: Segmentation, Industry trends and Development to 2027

Market Research Future (MRFR) claims that the arrhythmia monitoring devices market should progress at a rate of 6.44% from 2020 to 2027 (review period). The global market is also likely to USD 8,087.4 million by 2027.

Primary Boosters and Challenges

The COVID-19 outbreak has sent the arrhythmia monitoring devices market reeling with a number of challenges, in the form of travel bans and vulnerable supply chains. The lockdown has resulted in a huge demand-supply gap. There has been a sharp decline in the manufacturing rate across countries with the novel coronavirus causing the leading players huge losses. The relentless surge in the number of SARS-CoV-2 cases has been unfavorable for the business scenario, as economic conditions continue to deteriorate. Moreover, the healthcare industry is focusing mostly on bringing down these cases, which also works against the arrhythmia monitoring devices industry to some extent.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6714

With that said, the arrhythmia monitoring devices industry has the potential to maintain a steady growth throughout the review timeframe, as telecardiology continues to gain traction. Mounting awareness regarding the host of benefits these devices offer, such as convenient monitoring, ease of use and portability also foster their adoption rate. Latest studies confirm that close to 20 percent of adults worldwide are most likely to experience several types of premature ventricular heartbeats. Another report reveals that over 850,000 Americans have to be hospitalized due to arrhythmia every year. These statistics have been soaring rapidly and therefore, raise the need for advanced equipment and tools that can ensure effective and continuous monitoring. Expanding elderly population, in tandem with introduction of new and more innovative cardiac management monitoring devices should foster the growth trajectory of the global market.

Emergence of smart cardiac monitors, heavy burden of heart ailments and the rise in FDA approvals can also translate into considerable revenue generation in the next couple of years. Besides, the heightened preference for cost-effective electrocardiogram devices, and firms spending generously on R&D activities to come up with systems with better features should also favor the global market in the following years. Players frequently make strategic moves such as production expansion, technical innovations, and acquisition to improve their market rankings. Companies are also working on leveraging the potential of artificial intelligence, IoT and big data by integrating these technologies into their devices, to enhance their appeal.

Segmentation

Top segments considered in the study of the arrhythmia monitoring devices market include device type, application, and end user.

Device types analyzed in the report include mobile cardiac telemetry (MCT) devices, resting ECG, implantable cardiac monitor (ICM), Holter monitor, event monitor, among others.

Conduction disorders, premature ventricular contractions (PVC), tachycardia, ventricular fibrillation (V-fib), bradycardia and atrial fibrillation (A-fib) are some of the major applications covered in the report.

Home care settings, diagnostic centers, ambulatory surgery centers (ASC) and hospitals & clinics, are some of the top end-users in the market. The leading spot has been procured by the hospitals and clinics segment, which touched USD 1,740.0 Million in 2018.

Regional Status

Arrhythmia monitoring devices industry can be regionally divided into Europe, Asia Pacific (APAC), MEA or Middle East and Africa as well as the Americas.

America has emerged as the most profitable market, on account of the easy availability of highly innovative and effective options for arrhythmia, such as artificial pacemakers, antiarrhythmic drugs and implanted defibrillators. The region’s favorable reimbursement policies and the vast pool of renowned firms that spend significantly on rigorous R&D activities also enhance the market share.

Europe is currently the second most lucrative market, given that the adoption rate of cardiac arrhythmia monitors in the region is significantly high in line with the escalating cases of cardiac disorders. In 2018, the lead was taken by Spain in the region, accounting for a share of 5.5% in view of the surging use of smartphone applications bridging the communication gap between patients and doctors. Moreover, with clinics and hospitals striving to include arrhythmia care in routine treatment procedures, the European market is bound to fare well in the years to come.

Asia Pacific should progress at the fastest rate in the following years, as a result of the exploding population and the continuous surge in the use of latest technologies like wearables such as fitness monitors, mobile monitoring systems and fabric monitoring systems. Soaring preference for compact, home‐based, and portable monitoring devices along with the improving reimbursement scenario will also benefit the APAC market in subsequent years.

Prominent Contenders

Some of the affluent firms analyzed in the MRFR market study are Spacelabs Healthcare (US), Biotronik (Germany), Abbott Laboratories (US), Medtronic plc (Ireland), Alive Cor, Inc. (US), BioTelemetry, Inc. (US), Fukuda Denshi Co. Ltd (Japan), Applied Cardiac Systems Inc. (US), Nihon Kohden Corporation (Japan), GE Healthcare (US), and more.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/arrhythmia-monitoring-devices-market-6714

About Market Research Future:

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

Research report explores the Neurovascular Devices Market for the forecast period, 2020-2027

The global Neurovascular Devices Market will grow at a CAGR of 8.8% during the forecast period 2014 to 2023. The market for neurovascular devices is set to reach US$3.1 billion by 2023. As per Neurovascular Devices Market analysts, the global market is anticipated to witness growth owing to the factors such as top firms trying to ramp up their manufacturing capacity as well as increase in technological innovations. However, the Market will face challenges and restraints due to unfavorable reimbursement scenarios and the high cost of neurovascular devices during the forecast period 2014 to 2023.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5544

The consistently rising consumption of advanced neurovascular devices in the Market will support the growth. As per Market analysts, Neurovascular Devices Market based companies will face certain challenges during the forecast period 2014 to 2023. The Market research report provides in-depth analysis of the product, end-users, and therapeutic application segments. The Market research report presents factors such as lack of proficient neurosurgeons that could slow down the Market's growth.

Market Segmentation

The Neurovascular Devices Market has been segmented into product, end-users, and therapeutic application. Based on the segment which is the product, the market is categorized on the basis of embolization devices, support device, and aneurysm coiling. The global market for neurovascular devices is further segmented based on end-users into hemorrhagic and ischemic strokes. Furthermore, the market, on the basis of therapeutic is segmented into ambulatory surgical units and hospitals.

The Market report offers comprehensive study of the Neurovascular Devices Market segments including product, end-users, and therapeutic application. The analysts have also studied the Market's spread across the regional markets across many of the Market’s segments at country levels. The product, end-users, and therapeutic application segments spread across the Market along with the subsegments are studied. The global market for neurovascular devices is spread across various product and service based segments. The Market research report highlights these key segments and offers forecasts based on primary and secondary data. The global Neurovascular Devices Market research report presents key company profiles of organizations active across the Market.

Regional Overview

Expensive neurovascular devices may hinder the Market growth. The Market research report suggests that companies in the Market could be supported by companies exploring new ways to maintain their business as well as expanding patient pool during the forecast period. The Market is set to register growth at a high CAGR owing to these key factors. The Market is spread across North America, Europe, Asia-Pacific, and other parts of the world. As per Market analysts, Neurovascular Devices Market is set to witness tremendous growth across product, end-users, and therapeutic application segments. The global Market’s North American region covers Markets across the United States, Mexico, Canada, and others. Businesses present in the Market are also profiled and their strategies have been presented in detail in the Market research report.

The Market across the European region covers Italy, France, Germany, and the United Kingdom. Furthermore, Neurovascular Devices Market research report provides details about the APAC region covering Markets from China, India, Australia, Japan, and others. The Market is also active across several other parts of the world. The Market report covers all these key regions including the Middle East, Africa, Brazil, and others active in the global Market.

Competitive Landscape

Neurovascular devices has seen tremendous growth, due to interventional therapies witnessing massive growth and high demand for minimally invasive procedures. However, significant cost of neurovascular devices and the emergence of complications during neurovascular surgeries would challenge the companies active in the Market. Furthermore, companies using growth strategies to stay ahead in the global Market are expected to help the market during the forecast period 2014 to 2023. As Neurovascular Devices Market report suggests that the Market will register a CAGR of 8.8% and reach a US$3.1 billion by 2023, the market report highlights key areas Market based companies need to focus on. The Market research report projects a long term growth till 2023. Based on Market’s analysis on the basis of SWOT and Porters’ Five Force Model, Neurovascular Devices Market will rise during the forecast period 2014 to 2023, however the companies need to move ahead with caution. The Market research report highlights such key areas.

Industry News

Lazarus Effect, a medical equipment corporation with a highly acute ischemic stroke that is licenced in Europe but not in the United States, was acquired by Medtronic. The contract is a financial transaction of 100 million dollars, according to standard closing conditions. In the Medtronic neurovascular division of the Restaurant Therapy community Lazarus Effect would be included. Medina Medical, a provider of medical devices which is now in Medtronic's neurovascular business, developed a system to treat the cerebral aneurysm on 31 August. Lazarus' nitinol net cover plys over a stent recorder during the recuperation of the clot and wraps the clot around the stent.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/neurovascular-devices-market-5544

About Market Research Future:

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

Swab Market Current Trends, SWOT Analysis, Strategies, Industry Challenges, Business Overview and Forecast Research Study 2027

The global swab market is growing mainly due to the rising cases of surgery. According to a recent study report published by the Market Research Future, The global Swab market is booming and expected to gain prominence over the forecast period. The market is forecasted to demonstrate a spectacular growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period.

Swabs are medicated absorbent pads or materials, which are used as a part of surgery and medicine, pre-injection swabs, wound cleansers, or in a first aid kit. A swab consists of an absorbent material, which actually imparts the medical properties to the swab. These are pertained with antiseptics such as chlorhexidine, cetrimide or iodine or disinfectants such as alcohol. The antiseptics swabs that have active ingredients and show targeted and specific actions come under the medical products. On the other hand, alcohol swabs do not have active ingredient, thus, they do not show targeted action. According to the healthcare cost and utilization project report of the U.S. published in 2017, over 22 million surgeries were performed in 2014. Over 50% of these surgeries occurred in a hospital inpatient setting, which added a boost to the market growth. Furthermore, according to WHO report on global disease burden, by 2020 chronic diseases will account for almost three quarters of all deaths worldwide and 71% deaths will be on account on Ischaemic Heart Disease (IHD).

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/834

Notably, rising number of surgical procedures is the key factor driving the swab market. With the rising burden of chronic diseases, need of surgical procedures has also been escalating. As per the 2015 statistics suggested by Eurostat, cataract surgery, and colonoscopy were the two most common surgical procedures performed in European region. It is observed that in the year 2015, cataract surgery was performed one thousand times per 100 000 inhabitants specifically in Germany, Sweden, the Czech Republic, Luxembourg, Finland, Malta, Estonia, Austria, Portugal and France. Other common procedures include bronchoscopies, and transluminal coronary angioplasties. Road accidents have also found to be responsible for rising surgical procedures, occurrence of wounds due to injuries. For instance, according to a study published in the Journal of Injury and Violence Research in 2017, it is found that low and middle-income countries bear the major burden of road traffic incidents worldwide.

Other factors such as, favourable reimbursement scenario for a number of surgical procedures, huge funding for research & development, technological advancements, and rising approval from regulatory bodies are also fuelling the market growth. According to the American Medical Association, Medicare has made various significant amendments in Ambulatory Surgery Center payment system (ASC). It is observed that for incision and drainage postoperative wound infection Medicare was providing reimbursement of USD 790.85 which is now exceeded to USD 1,030.52 in ASC. Whereas hospital outpatient payment has been exceeded to USD 2,148.00 from USD 1,414.28 this year.

Despite these drivers, lack of awareness, and safety concerns are expected to decline the Swab market growth.

Global Swab Market - Competitive Analysis

Puritan Medical Products., Sarstedt, MWE, SARSTEDT AG & Co, Lab M Limited., Clean Cross Co.,LTD., GPC medical ltd., Citotest Labware Manufacturing Co., Ltd., Q-TIPS, and ELMEX are some of the prominent players at the forefront of competition in the Swab market and are profiled in MRFR Analysis.

The global swab market is currently dominated by few players.

Puritan Medical Products is one of them by holding a strong share in the market. As of Jan 21, 2000, Puritan-Bennett Corp. was acquired by Airgas Inc. Product portfolio of company is categorized in six major categories i.e. Controlled Environments, Diagnostics + Specimen Collection, Environmental, Forensics + Genetics, Microbiology Media, and Medical. Swab is covered under Forensics + Genetics, which includes Puritan 5" Sterile Large Round Foam Swab w/Polypropylene Handle, PurFlock Ultra 6" Sterile DNA-Free Standard Flock Swab w/Plastic Handle & Tube, HydraFlock 6" Sterile Large Flock Swab w/Polystyrene Handle, 80mm Breakpoint, Puritan 6" Sterile Standard Cotton Swab w/Wooden Handle, Fab-Swab 5" Sterile DNA Controlled Mini-tip Cotton Swab w/Wood Handle & Tube, and many others.

Sarstedt, Inc. is also one of the leading player in Swab market. The company develops, manufactures, and sells equipment and consumables in the medicine and research field. Product portfolio of company includes diagnostic products, laboratory products.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/swab-market-834

About Market Research Future:

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

Arachnoiditis Market Foraying into Emerging Economies 2020-2027

Arachnoiditis is a rare disorder related to the spine which is caused by damage to the arachnoid layer. According to the scientists and researchers, arachnoiditis is not curable, but the pain caused by the disease can be controlled by using combined therapies. The growth of the global arachnoiditis market is depended on increasing geriatric population along with rising number of surgical procedures, increasing healthcare expenditure, and favorable reimbursement policies. According to the US Centers for Medicare & Medicaid Services, the US has spent USD 3.3 trillion on healthcare in the year 2016 which is approximately USD 10,348 per person.

The high costs associated with the treatment of arachnoiditis, stringent regulatory environment for product approval, and a dearth of experts are likely to hinder the market growth during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6556

Regional Analysis

The market in the Americas is expected to dominate the global arachnoiditis market during the forecast period due to the rising number of surgeries, technological advancement along with high adoption rate, and favorable regulatory and government authorities. The European market is expected to hold the second position in global arachnoiditis market, factors responsible for the growth of the market in the European region are government support and increasing spending on healthcare, growing geriatric population and increasing research and development activities in the region. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing market during the forecast period owing to the constantly increasing population, increasing number of chronic diseases like tuberculosis and acute back pain due to the changing lifestyle. The market in the Middle East & Africa is likely to account for the smallest share of the global arachnoiditis market. The market growth in this region can be attributed to the increasing development and rising investment in the healthcare sector.

The American region is likely to hold the maximum market share and the US will dominate the country level market.

Segmentation

The global arachnoiditis market has been classified on the basis of type, cause, diagnosis, treatment, and end-user.

The market, by type, has been classified as adhesive arachnoiditis, arachnoiditis ossificans, arachnoiditis ossificans, cerebral arachnoiditis, hereditary arachnoiditis, neoplastic arachnoiditis, and optochiasmatic arachnoiditis.

On the basis of cause, the market has been segmented into trauma/surgery induced, chemically induced, and infection-induced. The trauma/surgery induced segment is divided into spinal surgery, lumbar puncture, spinal stenosis, and others. The chemically induced segment is further divided into myelograms and epidural steroid injection. The infection-induced segment is classified into viral and fungal meningitis, and tuberculosis.

Diagnosis segment has been classified into CAT scan (computerized axial tomography), MRI (magnetic resonance imaging), and Electromyogram (EMG).

Based on treatment, the market has been divided into Physical therapy, Pain medications, Nerve stimulation, and psychological support. The physical therapy segment is further divided into hydrotherapy, massage, and hot/cold therapy. lidocaine intravenous (IV) infusion, ketamine IV infusions, and naltrexone are part of pain medications. Nerve stimulation segment is divided into spinal cord stimulation, and transcutaneous electrical nerve stimulation (TENS).

The market on the basis of end-user has been segmented on the basis of hospital and clinics, pharmacies, diagnostic centers, and others.

The pain medication segment will register the maximum market share during the forecast period and nerve stimulation treatment segment will be the fastest growing segment.

Key Players

Some of the key players in the global arachnoiditis market are Bristol-Myers Squibb Company, Abbott, Pfizer Inc., Baxter, B. Braun Melsungen AG, SR Pharma, AstraZeneca, DuPont, Sandoz International GmbH, Takeda Pharmaceutical Company Limited, and Novartis AG.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/arachnoiditis-market-6556

About Market Research Future:

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com